Svar Life Science AB

Reminder! The application deadline for the Svar Life Science Complement Excellence Award is approaching fast! Don't miss your chance to be recognized for your outstanding contributions to the Complement field. We offer two grants of 20,000 EUR each to support innovative research and celebrate your contributions. Deadline: June 1st at 00:00 CET It's easy to apply or nominate a deserving peer. Visit our website for more details: https://hubs.ly/Q02xK4W_0 Let's continue to drive excellence in the Complement field together! #ComplementScience #ResearchAward #LifeScience #Innovation #ComplementingLifeScience #SvarLifeScience #ExpertPartner

Monoclonal antibodies (mAbs) have harnessed the power of complement‐dependent cytotoxicity (CDC) to target and eliminate harmful cells. In the process of mAb development, it is crucial to profile the CDC activity to gain a comprehensive understanding of its Fc-mediated anti-tumor function. Learn more the relevance of antibody-induced CDC and how to measure the potency of CDC induction or inhibition using an advanced functional bioassays. https://hubs.ly/Q02FlvHx0 #ComplementingLifeScience #AnswersinLifeScience #Complementbiology #ComplementResearch #AlternativePathway #ComplementSystem #ImmuneResponse #ImmuneSystem #Drugdevelopment #Therapeutics #MonoclonalAntibodies #TherapeuticAntibodies #AntibodyEngineering #CDC

Interested in the advancements in complement therapeutics? Don't miss our latest case study showcasing an alternative use of our Properdin assay. Learn about functional assessment of Properdin and the AP- C3 convertase and its impact on drug development. https://hubs.ly/Q02DSnHZ0 #ComplementingLifeScience #AnswersinLifeScience #Complementsystem #Complementbiology #AlternativePathway #Properdin #drugdevelopment

Enhance your research with Olink® Immune biomarker profiling! By combining Olink Target 48 Cytokine and Olink Target 48 Immune Surveillance panels, you gain comprehensive coverage of key immunological processes and robust protein biomarker signatures across major therapeutic areas. Enjoy a 30% discount on combined panels until September 2024. Contact us today! ▶️https://hubs.ly/Q02Gl3Xt0 #bioanalyticalservices #svarlifescience #drugdevelopment #CRO #biomarkerdiscovery

Dive into cutting-edge antibody development with the Fc Effector assay platform, which offers precision assays for #ADCC, #ADCP, and #CDC with superior sensitivity and dynamic range. #AntibodyEngineering #Fceffector #mAbs #innovation #iLite #ComplementingLifeScience #AnswersinLifeScience https://hubs.ly/Q02DRtS10

In this month's #ComplementinLifeScience, a recent article reports the use of #riliprubart in treating cold agglutinin disease (#CAD). Riliprubart is a second-generation inhibitor that selectively inhibits the activated form of C1s. CAD is a rare autoimmune disease that causes hemolytic anemia mediated by the classical complement pathway (CP). In a phase 1b clinical trial, the safety and efficacy of riliprubart were assessed in CAD patients. Riliprubart's activity on CP and AP was determined by #Wieslabassays. The lack of change in Wieslab AP activity from baseline to the end of the study demonstrated its specificity for CP. The study also reports that in this cohort, a single dose led to a reduction in hemolytic complement, resolution of hemolysis, and correction of anemia, with responses maintained over the 15 weeks of the study with no serious adverse events. Read the full article here: https://hubs.ly/Q02FlTd_0 #Complementbiology #Complementresearch #ComplementTherapeutics #Articleofthemonth #ResearchArticleAlert

Ready to revolutionize your biomarker discovery? Try the new Olink® Immune biomarker profiling with absolute confidence! By combining Olink Target 48 Cytokine and Olink Target 48 Immune Surveillance panels, you can detect biomarkers covering key immunological processes and identify robust protein biomarker signatures across major therapeutic areas. Learn more about this offer and enjoy a 30% discount until the end of September 2024: Contact us today! ▶️ https://hubs.ly/Q02G9npN0 #bioanalyticalservices #svarlifescience #answersinlifescience #expertpartner #drugdevelopment #CRO #biomarkerdiscovery 

The iLite® CDC bioassays ensure consistency and reproducibility, providing quantitative results that enable accurate measurement and comparison of CDC response across samples. This quantitative data empowers the optimization of therapeutic antibody candidates. Say goodbye to complex setups! The iLite® CDC assay offers standardized, reliable antibody-induced CDC cell lysis measurement. The answers you seek for informed decision-making are in Svar Assays. Learn more! https://hubs.ly/Q02DSlY40 #bispecificantibodies #bioassay #cellbasedassays #iLite #iLiteTechnology #CDC #ComplementBiology #ComplementingLifeScience #ComplementTherapeutics #Antibodies #Antibodyengineering #immunooncology

Regulatory hurdles and assay complexity can impede your therapeutic development progress. Svar offers comprehensive CRO services and iLite® cell-based products tailored to meet your specific needs, ensuring precision and compliance at every stage of your project. Learn more! https://hubs.ly/Q02Fl69q0 #ExpertPartner #CROservices #Immunogenicity #NAbs #TAbs #ADAs #Antibodies #Proteins #Oligonucleotides #Biosimilars #AAVcapsids #Monoclonal #Fusion #Reombinant #Compliance #ComplementingLifeScience #Cellbasedassays

The iLite® Complement-Dependent Cytotoxicity (CDC) Bioassays are a truly reflective Complement Dependent Cytotoxicity cell lysis assay, developed by our cell engineer experts and scientists to address the limitations of traditional assay technologies in therapeutic antibody development. Read the editorial article to uncover the smart engineering behind it by the scientists who developed it! https://hubs.ly/Q02DRjFn0 #bispecificantibodies #bioassay #cellbasedassays #iLite #iLiteTechnology #CDC #ComplementBiology #ComplementingLifeScience #ComplementTherapeutics #Antibodies #antibodyengineering